-
-
-
-
-
-
-
Savara (SVRA) Granted Breakthrough Therapy Designation for Molgradex for Treatment of aPAP
-
-
-
-
-
-
-
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference
-
-
-
-
-
-
-
Savara to Report First Quarter 2019 Financial Results and Provide Business Update
-
-
-
-
-
-
-
Savara (SVRA) Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
-
-
-
-
-
-
-
Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
-
-
-
-
-
-
-
Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM
-
1,163,953 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

